THE DIAGNOSTIC VALUE OF OSTEOPONTIN AS AN EARLY MARKER OF PILMONARY HYPERTENSION AFFECTED BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CONCOMITANT ISCHEMIC HEART DISEASE.
The article highlights the results of the study of the influence of osteopontin on the development of pulmonary hypertension in patients with COPD in combination with IHD. 121 patients with established diagnosis of COPD and IHD were randomized for the study, all patients underwent general clinical examination, spirography, ECG to determine the level of pulmonary artery pressure, a questionnaire according to the Borg and mMRC scales, and a 6-minute walk test. All patients were divided into 2 groups: group 1 (63 people) with the increased PA pressure, group 2 - comparison group - without PH (58 people). The conducted study suggests that the concentration of circulating osteopontin above 38.25 ng/ml can be considered as an early marker and an independent predictor of pulmonary hypertension in patients with COPD and concomitant IHD. In the PH (main) group osteopontin statistically significantly positively correlated with the age of patients, the right atrial area and the plasma level of interleukin 2 (IL-2). Interleukin 4 (IL-4), which is a marker of anti-inflammatory plasma activity, does not correlate with either pulmonary hypertension or osteopontin level, which indicates insufficient.